X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (17397) 17397
Book Review (1508) 1508
Publication (635) 635
Newsletter (246) 246
Conference Proceeding (40) 40
Book Chapter (31) 31
Magazine Article (27) 27
Newspaper Article (22) 22
Dissertation (6) 6
Transcript (4) 4
Trade Publication Article (3) 3
Data Set (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (15314) 15314
humans (13077) 13077
male (7243) 7243
female (7144) 7144
cytarabine - administration & dosage (6503) 6503
middle aged (5577) 5577
adult (5540) 5540
antineoplastic combined chemotherapy protocols - therapeutic use (4800) 4800
oncology (4475) 4475
hematology (4281) 4281
cytarabine - therapeutic use (3820) 3820
aged (3809) 3809
cytarabine - pharmacology (3716) 3716
cytarabine (3449) 3449
animals (3300) 3300
adolescent (3230) 3230
leukemia, myeloid, acute - drug therapy (3156) 3156
chemotherapy (2493) 2493
remission induction (2261) 2261
treatment outcome (2139) 2139
child (1970) 1970
cytarabine - adverse effects (1858) 1858
mice (1773) 1773
cancer (1761) 1761
abridged index medicus (1682) 1682
prognosis (1668) 1668
antineoplastic combined chemotherapy protocols - adverse effects (1551) 1551
acute disease (1461) 1461
daunorubicin - administration & dosage (1431) 1431
leukemia (1397) 1397
acute myelogenous leukemia (1371) 1371
etoposide - administration & dosage (1363) 1363
child, preschool (1334) 1334
antineoplastic combined chemotherapy protocols - administration & dosage (1301) 1301
therapy (1280) 1280
time factors (1268) 1268
acute myeloid-leukemia (1264) 1264
methotrexate - administration & dosage (1237) 1237
cyclophosphamide - administration & dosage (1222) 1222
vincristine - administration & dosage (1220) 1220
acute myeloid leukemia (1188) 1188
combined modality therapy (1147) 1147
antineoplastic agents - therapeutic use (1118) 1118
disease-free survival (1107) 1107
dose-response relationship, drug (1067) 1067
recurrence (1040) 1040
leukemia - drug therapy (1012) 1012
survival rate (977) 977
leukemia, myeloid - drug therapy (949) 949
drug administration schedule (947) 947
drug therapy, combination (936) 936
doxorubicin - administration & dosage (908) 908
transplantation (903) 903
aged, 80 and over (885) 885
retrospective studies (883) 883
cell line (864) 864
survival analysis (858) 858
infant (837) 837
leukemia, myeloid, acute - mortality (835) 835
cytosine-arabinoside (780) 780
follow-up studies (780) 780
cells, cultured (779) 779
leukemia, myeloid, acute - pathology (772) 772
young adult (763) 763
pharmacology & pharmacy (729) 729
prednisone - administration & dosage (727) 727
research (717) 717
antineoplastic agents - pharmacology (711) 711
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (702) 702
high-dose cytarabine (689) 689
daunorubicin - therapeutic use (678) 678
aml (676) 676
survival (665) 665
vincristine - therapeutic use (663) 663
care and treatment (657) 657
cytarabine - metabolism (657) 657
cyclophosphamide - therapeutic use (652) 652
antineoplastic agents - administration & dosage (640) 640
bone marrow transplantation (639) 639
cytarabine - analogs & derivatives (635) 635
kinetics (633) 633
mitoxantrone - administration & dosage (626) 626
hematopoietic stem cell transplantation (625) 625
apoptosis (609) 609
leukemia, myeloid, acute - genetics (607) 607
idarubicin - administration & dosage (599) 599
risk factors (598) 598
rats (593) 593
medicine & public health (586) 586
methotrexate - therapeutic use (577) 577
ara-c (576) 576
leukemia, myeloid, acute - therapy (564) 564
drug resistance (559) 559
cell division - drug effects (556) 556
transplantation, autologous (549) 549
drug synergism (545) 545
cell survival - drug effects (543) 543
children (540) 540
acute lymphoblastic-leukemia (525) 525
lymphoma, non-hodgkin - drug therapy (511) 511
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (15721) 15721
Japanese (624) 624
German (307) 307
Chinese (242) 242
French (230) 230
Russian (161) 161
Spanish (140) 140
Polish (103) 103
Italian (85) 85
Czech (23) 23
Hungarian (14) 14
Danish (12) 12
Portuguese (12) 12
Dutch (10) 10
Korean (8) 8
Norwegian (6) 6
Hebrew (5) 5
Turkish (5) 5
Romanian (4) 4
Serbian (4) 4
Slovak (4) 4
Swedish (4) 4
Croatian (3) 3
Arabic (1) 1
Bosnian (1) 1
Bulgarian (1) 1
Indonesian (1) 1
Persian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 03/2007, Volume 109, Issue 6, pp. 1114 - 1124
Journal Article
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 10/2014, Volume 473, Issue 1-2, pp. 560 - 571
The synthesized cytarabine-AOT amphiphilic molecules can self-assemble into vesicles in aqueous solution for realizing the sustained release of its component... 
Catanionic vesicle | Sustained drug release | Cytarabine-AOT amphiphile | Thermosensitive hydrogel | CYTOSINE-ARABINOSIDE | DRUG-DELIVERY | SURFACTANTS | ANTICANCER DRUG | MICELLES | COPOLYMERS | RELEASE | MIXTURES | IN-VITRO EVALUATION | FORMULATIONS | PHARMACOLOGY & PHARMACY | Hemolysis - drug effects | Antimetabolites, Antineoplastic - pharmacokinetics | Hydrogels | Humans | Dioctyl Sulfosuccinic Acid - chemistry | Drug Carriers - administration & dosage | Surface-Active Agents - pharmacokinetics | Delayed-Action Preparations - chemistry | Polyethylene Glycols - chemistry | Drug Carriers - chemistry | Antimetabolites, Antineoplastic - administration & dosage | Delayed-Action Preparations - administration & dosage | Cytarabine - pharmacokinetics | Antimetabolites, Antineoplastic - blood | Delayed-Action Preparations - pharmacokinetics | Polyglactin 910 - chemistry | Cytarabine - blood | Cell Survival - drug effects | Rabbits | Dioctyl Sulfosuccinic Acid - administration & dosage | Membranes, Artificial | Antimetabolites, Antineoplastic - chemistry | Dioctyl Sulfosuccinic Acid - pharmacokinetics | Hot Temperature | Permeability | Cytarabine - administration & dosage | Erythrocytes - drug effects | Animals | Cytarabine - chemistry | Surface-Active Agents - administration & dosage | K562 Cells | Drug Liberation | HL-60 Cells | Drug Carriers - pharmacokinetics | Surface-Active Agents - chemistry | Drugs | Drug delivery systems | Cytarabine | Vehicles | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2012, Volume 30, Issue 21, pp. 2670 - 2677
Journal Article
CANCER, ISSN 0008-543X, 12/2017, Volume 123, Issue 24, pp. 4935 - 4936
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 10, pp. 917 - 927
Journal Article
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 21, pp. 3239 - 3246
Journal Article
Journal Article
Nature Medicine, ISSN 1078-8956, 02/2017, Volume 23, Issue 2, pp. 250 - 255
Journal Article
British Journal of Haematology, ISSN 0007-1048, 07/2017, Volume 178, Issue 1, pp. 106 - 111
The efficacy of high‐dose cytarabine ( HDCA ) plus cyclophosphamide/total‐body irradiation ( CY / TBI ) has been proved in cord blood transplantation ( CBT )... 
BMT | allogeneic transplantation | PBSCT | high‐dose cytarabine | acute lymphoblastic leukaemia | conditioning regimens | BMT/PBSCT | high-dose cytarabine | CORD BLOOD TRANSPLANTATION | RISK-FACTORS | PROGNOSIS | MARROW-TRANSPLANTATION | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Japan - epidemiology | Recurrence | Whole-Body Irradiation | Cyclophosphamide - administration & dosage | Peripheral Blood Stem Cell Transplantation - adverse effects | Prognosis | Peripheral Blood Stem Cell Transplantation - methods | Humans | Middle Aged | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Cytarabine - adverse effects | Bone Marrow Transplantation - methods | Cyclophosphamide - adverse effects | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | Adult | Female | Registries | Transplantation Conditioning - adverse effects | Transplantation Conditioning - methods | Kaplan-Meier Estimate | Combined Modality Therapy | Cytarabine - administration & dosage | Adolescent | Bone Marrow Transplantation - adverse effects | Aged | Analysis | Mortality | Bone marrow | Adults | Transplantation | Health aspects | Hematopoietic stem cells | Acute lymphatic leukemia | Transplants & implants | Leukemia | Radiation | Bone marrow transplantation | Stem cell transplantation | Blood | Extrapolation | Cyclophosphamide | Cytarabine | Rope | Cord blood | Medical prognosis | Peripheral blood | Irradiation | Index Medicus
Journal Article
Hematological Oncology, ISSN 0278-0232, 02/2018, Volume 36, Issue 1, pp. 110 - 115
Implementation of cytarabine into induction therapy became standard of care for younger patients with mantle cell lymphoma (MCL). On the basis of its... 
elderly patients | mantle cell lymphoma | high‐dose cytarabine | PET‐CT | rituximab maintenance | PET-CT | high-dose cytarabine | BENDAMUSTINE | MULTICENTER | IMMUNOCHEMOTHERAPY | PLUS RITUXIMAB | OPEN-LABEL | TRIAL | THERAPY | DOSE CYTARABINE | ONCOLOGY | HEMATOLOGY | Doxorubicin - therapeutic use | Vincristine - pharmacology | Cytarabine - pharmacology | Cytarabine - therapeutic use | Humans | Middle Aged | Lymphoma, Mantle-Cell - pathology | Lymphoma, Mantle-Cell - drug therapy | Male | Cyclophosphamide - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cyclophosphamide - pharmacology | Vincristine - therapeutic use | Aged, 80 and over | Female | Prednisone - pharmacology | Aged | Antibodies, Monoclonal, Murine-Derived - pharmacology | Doxorubicin - pharmacology | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Medicine, Experimental | Medical research | CT imaging | Lymphomas | PET imaging | Analysis | Elderly people | Therapy | Toxicity | Feasibility studies | Positron emission | Health risks | Rituximab | Survival | Patients | Lymphoma | Emissions | Cytarabine | Computed tomography | Mantle cell lymphoma | Tomography | Mantle | Positron emission tomography | Elderly | Geriatrics | Index Medicus
Journal Article